Latest news with #DelhiHC
New Indian Express
16 hours ago
- General
- New Indian Express
Hundreds lose homes as bulldozers raze Delhi's Madrasi Camp slum
NEW DELHI: Residents of Madrasi Camp in south Delhi's Jungpura watched helplessly as bulldozers razed homes they had lived in for decades, leaving hundreds of working-class families displaced. The demolition drive, conducted by civic authorities on Monday, followed a Delhi HC order that cited obstruction to drain cleaning that contributes to monsoon flooding. 'We have nowhere to go now,' said 67-year-old Lakshmi, whose family has lived in the camp for almost sixty years. 'We cannot afford to pay rent in nearby localities. If we move further away, we will lose our source of income,' she added. Around 370 families, mostly of Tamil origin, lived in Madrasi Camp, a settlement over 60 years old. While eviction notices were served last month, only 189 families were found eligible for relocation to government-allotted flats in Narela, as per a list released on April 12. A May 30 notice informed residents that trucks would be stationed near the bridge to help transport belongings.
New Indian Express
a day ago
- Politics
- New Indian Express
Tamil Nadu government offers support to families in Delhi's Madrasi Camp who wish to return to their native districts
The Tamil Nadu House in New Delhi has been tasked with actively facilitating and overseeing coordination efforts. 'Reaffirming its unwavering commitment to the welfare of persons of Tamil Nadu origin residing outside the State, the Tamil Nadu government is in active coordination with the residents of Madrasi Camp to ensure that every possible support is extended to them without any delay,' the release added. The Madrasi Camp is a settlement comprising 370 slum dwellings and is predominantly inhabited by persons of Tamil Nadu origin. The Delhi HC directed that eligible residents be rehabilitated and relocated under the provisions of the Delhi Urban Shelter Improvement Board (DUSIB) Act and the Delhi Slum & JJ Rehabilitation and Relocation Policy, 2015. The Delhi Urban Shelter Improvement Board has determined that 215 out of the 370 residents are eligible for allotment. Accordingly, these eligible beneficiaries have been allotted residential units under the Economically Weaker Section (EWS) category of the Delhi Development Authority (DDA) located in Narela, Delhi. Furthermore, all legal petitions filed by the residents of Madrasi Camp have been adjudicated and disposed of by the Delhi HC on May 9, and the order mandated the commencement of demolition activities at Madrasi Camp on June 1. All legal avenues available to the residents of Madrasi Camp for retaining the unauthorised constructions at the site have been duly exhausted.
New Indian Express
2 days ago
- Politics
- New Indian Express
Plea to halt demolition of refugee camp rejected
NEW DELHI: The Delhi HC has turned down a plea asking the Delhi Development Authority not to remove or demolish a refugee camp set up by Pakistani-Hindu migrants at Majnu Ka Tila, unless they are first given another place to live. Justice Dharmesh Sharma, who delivered the verdict on May 30, made it clear that the petitioner, Ravi Ranjan Singh, and others living in similar conditions, have 'no right to continue to occupy the area in question.' The Court also lifted the interim protection it had granted on March 13 last year, which had barred the DDA from taking action against Singh. The refugee settlement in question lies in the Yamuna floodplains, a highly sensitive ecological zone. The Court noted that the National Green Tribunal (NGT) has already given clear instructions to government bodies like the DDA to reclaim such areas from illegal occupation and to begin work on restoring the Yamuna's ecological health.
Economic Times
3 days ago
- Business
- Economic Times
Big fat legal war bursts out ahead of Novo Nordisk's Wegovy launch
Live Events Next Hearing on Aug 19 (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel A high-stakes legal battle has erupted ahead of the anticipated launch of Novo Nordisk 's blockbuster weightloss drug Wegovy (semaglutide) in India. The Delhi High Court has restrained Dr Reddy's Laboratories (DRL) and OneSource Specialty Pharma from selling semaglutide in the domestic market, following a patent infringement plea by the Danish the court, in an interim order Thursday, has not barred the Indian companies from manufacturing and exporting the drug. 'The defendants have alicence to manufacture the impugned drug, which was granted in December 2024, and have begun manufacturing the drug in April 2025,' noted the order uploaded late added that 'the defendants reserve their right to export the impugned drug in countries where the plaintiff has not been granted a patent yet'.Novo Nordisk on May 26 filed a patent infringement suit against Hyderabad-based Dr Reddy's and contract drugmaker OneSource before the Delhi HC. This was a countermove after Dr Reddy's on May 14 moved the HC seeking revocation of Novo Nordisk's patent for semaglutide—the active ingredient in Wegovy and Ozempic, the Danish firm's popular obesity and diabetes drugs. Novo Nordisk has alleged that Dr Reddy's and OneSource are importing large quantities of semaglutide active pharmaceutical ingredient (API) into India, and using it to manufacture and export violated Novo's patent rights, it claimed.A single-judge bench of the Delhi HC has posted the matter for further hearing on August 19, along with Dr Reddy's patent challenge, a senior lawyer told experts expect Novo Nordisk to appeal the interim order before a division bench as the single bench has not restrained the Indian companies from exporting semaglutide. 'Novo Nordisk is taking active steps to protect its inventions in India,' a company spokesperson said. The company said its semaglutide patents are protected in India and it expects continued support and protection of innovation in the country. 'However, we would not like to comment on a sub-judice matter,' the spokesperson a statement to ET, a Dr Reddy's spokesperson said, 'The matter is currently sub judice. We are unable to comment on it at this time.'A spokesperson for OneSource, too, declined comment citing the same a 650-page petition, Novo Nordisk said it became aware of the infringements of its valid patent number IN 262697 in India in October and November 2024.
Time of India
3 days ago
- Business
- Time of India
Big Fat Legal War Bursts Out aheadof Wegovy Launch
Live Events A high-stakes legal battle has erupted ahead of the anticipated launch of Novo Nordisk 's blockbuster weight-loss drug Wegovy (semaglutide) in India. The Delhi High Court has restrained Dr Reddy's Laboratories (DRL) and OneSource Specialty Pharma from selling semaglutide in the domestic market, following a patent infringement plea by the Danish the court, in an interim order Thursday, has not barred the Indian companies from manufacturing and exporting the drug. 'The defendants have a licence to manufacture the impugned drug, which was granted in December 2024, and have begun manufacturing the drug in April 2025,' noted the order uploaded late added that 'the defendants reserve their right to export the impugned drug in countries where the plaintiff has not been granted a patent yet'.Novo Nordisk on May 26 filed a patent infringement suit against Hyderabad-based Dr Reddy's and contract drugmaker OneSource before the Delhi HC. This was a countermove after Dr Reddy's on May 14 moved the HC seeking revocation of Novo Nordisk's patent for semaglutide— the active ingredient in Wegovy and Ozempic, the Danish firm's popular obesity and diabetes drugs. Novo Nordisk has alleged that Dr Reddy's and OneSource are importing large quantities of semaglutide active pharmaceutical ingredient (API) into India, and using it to manufacture and export violated Novo's patent rights, it claimed.A single-judge bench of the Delhi HC has posted the matter for further hearing on August 19, along with Dr Reddy's patent challenge, a senior lawyer told experts expect Novo Nordisk to appeal the interim order before a division bench as the single bench has not restrained the Indian companies from exporting semaglutide.'Novo Nordisk is taking active steps to protect its inventions in India,' a company spokesperson said. The company said its semaglutide patents are protected in India and it expects continued support and protection of innovation in the country. 'However, we would not like to comment on a sub-judice matter,' the spokesperson a statement to ET, a Dr Reddy's spokesperson said, 'The matter is currently sub judice. We are unable to comment on it at this time.'A spokesperson for OneSource, too, declined comment citing the same a 650-page petition, Novo Nordisk said it became aware of the infringements of its valid patent number IN 262697 in India in October and November 2024.
